Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020

Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ: CDMO) announced it will release financial results for the quarter and fiscal year ending April 30, 2020, on June 30, 2020, post-market. A conference call at 1:30 PM PT (4:30 PM ET) will follow, with company executives discussing the results and recent developments. Avid specializes in biologics contract development and manufacturing, offering comprehensive services including clinical and commercial drug substance manufacturing, and process development, leveraging over 25 years of experience in the biopharmaceutical sector.

TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2020 on June 30, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2020 and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 25 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs, the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com 

Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401


Tim Brons (Media)
Vida Strategic Partners
415-675-7402

FAQ

When will Avid Bioservices report its financial results for FY 2020?

Avid Bioservices will report its financial results for the fiscal year ending April 30, 2020, on June 30, 2020.

What time is the Avid Bioservices conference call scheduled?

The conference call is scheduled for June 30, 2020, at 1:30 PM Pacific Time (4:30 PM Eastern Time).

How can I access the Avid Bioservices earnings call webcast?

You can access the live and archived webcast of the earnings call on Avid Bioservices' investor events page.